Cell line
|
SH-SY5Y
|
SK-Br3
|
C2C12
|
EA.hy926
|
Compound/Fraction
|
Solamargine
|
Aqueous alkaloid-enriched fraction
|
Solamargine
|
Aqueous alkaloid-enriched fraction
|
Solamargine
|
Aqueous alkaloid-enriched fraction
|
Solamargine
|
Aqueous alkaloid-enriched fraction
|
IC50 of (A) [IC50 sample + doxorubicin (μM or μg/mL)]
|
3.4
|
7.39
|
4.3
|
11.18
|
30.77
|
15.7
|
5.5
|
2.62
|
IC50 of (B) [IC50 doxorubicin + sample (nM)]
|
16.27
|
24.22
|
40.83
|
47.48
|
149.9
|
140.7
|
213.4
|
220
|
IC50 (A) [Solamargine (μM) or aqueous alone (μg/mL)]
|
15.62
|
26.5
|
18.59
|
19.7
|
20.25
|
13.7
|
8.3
|
7.3
|
IC50 (B) [doxorubicin alone (nM)]
|
56.6
|
56.6
|
94.1
|
94.1
|
148.5
|
148.5
|
381.6
|
381.6
|
FIC (A)
|
0.22
|
0.28
|
0.23
|
0.57
|
1.52
|
1.15
|
0.66
|
0.36
|
FIC (B)
|
0.29
|
0.43
|
0.43
|
0.5
|
1.01
|
0.95
|
0.56
|
0.58
|
FIX value
|
0.51
|
0.71
|
0.66
|
1.07
|
2.53
|
2.1
|
1.22
|
0.94
|
Result
|
Additive effect
|
Additive effect
|
Additive effect
|
Indifferent effect
|
Antagonistic effect
|
Antagonistic effect
|
Indifferent effect
|
Additive effect
|